Term,Overlap.x,P.value.x,Adjusted.P.value.x,Old.P.value.x,Old.Adjusted.P.value.x,Odds.Ratio.x,Combined.Score.x,Genes.x,Overlap.y,P.value.y,Adjusted.P.value.y,Old.P.value.y,Old.Adjusted.P.value.y,Odds.Ratio.y,Combined.Score.y,Genes.y
Cochlear Inflammation (Noise-Induced),3/12,8.09023401191225e-06,0.000469233572690911,0,0,102.169230769231,1197.91920180223,TGFB1;PECAM1;ICAM1,1/12,0.00179897576875959,0.00907107167013115,0,0,908.454545454545,5741.92128812022,CCL2
Hexosamine Pathway in Diabetic Microangiopathy,2/11,0.000614179683482303,0.00647680393490428,0,0,67.0808080808081,496.077536690995,TGFB1;SERPINE1,1/11,0.00164914273085112,0.00907107167013115,0,0,999.35,6403.33480835207,PLAU
Proteins with Altered Expression in Systemic Scleroderma,2/12,0.000735398408705035,0.00699231273850689,0,0,60.369696969697,435.573289100152,PDGFRA;TGFB1,1/12,0.00179897576875959,0.00907107167013115,0,0,908.454545454545,5741.92128812022,CCL2
Fibroblast growth factor 1,3/26,9.24081080033793e-05,0.00258742702409462,0,0,39.9511705685619,371.118242334436,CDKN1A;SERPINE1;TCF4,1/26,0.00389506923436901,0.0153069028079862,0,0,399.44,2216.11062530876,PLAU
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,4/42,1.24082887227302e-05,0.00059676389367213,0,0,32.7203947368421,369.647072046267,TGFB1;ITGB5;SERPINE1;ITGA5,1/42,0.00628701524151983,0.0158764156607123,0,0,243.365853658537,1233.6869399593,PLAU
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling Homo sapiens 503076a2-6196-11e5-8ac5-06603eb7f303,4/42,1.24082887227302e-05,0.00112915427376845,0,0,32.7203947368421,369.647072046267,TGFB1;ITGB5;SERPINE1;ITGA5,1/42,0.00628701524151983,0.00901093861824211,0,0,243.365853658537,1233.6869399593,PLAU
Proteins Involved in Systemic Scleroderma,4/49,2.30715742210139e-05,0.000892100869879204,0,0,27.6208333333333,294.905130947814,PDGFRA;SPARC;TGFB1;ICAM1,1/49,0.00733228757304079,0.0126861105462276,0,0,207.802083333333,1021.44443446465,CCL2
Platelet-mediated interactions with vascular and circulating cells WP4462,2/17,0.00149882310777215,0.0131014292074948,0,0,40.2363636363636,261.660093417879,TGFB1;ICAM1,1/17,0.00254791692627063,0.0151023883026845,0,0,624.40625,3729.25330632509,CCL2
Proteins Involved in Prostate Cancer,7/138,4.36143306101235e-07,6.3240779384679e-05,0,0,17.3453885621324,254.028331755602,CDKN1A;TGFB1;CDH1;TGFB1I1;ILK;ADAM9;CLU,2/138,0.000141153874297156,0.00150136393570611,0,0,292.073529411765,2589.42459378401,PLAU;CCL2
RAGE pathway,4/60,5.16282093447673e-05,0.00206339134872099,0,0,22.1830357142857,218.978558026998,TGFB1;SERPINE1;ITGA5;ICAM1,1/60,0.00897337803301339,0.0177648263113934,0,0,168.966101694915,796.42055134622,CCL2
Proteins Involved in Glioma,10/290,4.87284211137037e-08,2.82624842459481e-05,0,0,12.1009852216749,203.74432909464,PDGFRA;CDKN1A;SPARC;TGFB1;ELMO1;ILK;SLC2A3;ITGA5;DKK1;LIMS1,3/290,3.01738014815311e-06,0.000276095361914298,0,0,59130,751608.620425921,CYP27B1;PLAU;CCL2
LRRK2 activemutant 159 GSE36321,10/300,6.69528976925832e-08,6.66181332041203e-06,0,0,11.6777645659929,192.908221584235,LDHB;CDKN1A;SPARC;ITGB5;FHL1;TPM1;ELMO1;SLC2A3;TFPI;TNS3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LRRK2 mutant 33 GDS4401,10/300,6.69528976925832e-08,6.66181332041203e-06,0,0,11.6777645659929,192.908221584235,LDHB;CDKN1A;SPARC;ITGB5;FHL1;TPM1;ELMO1;SLC2A3;TFPI;TNS3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
Advanced Glycation End Products Pathway in Diabetic Microangiopathy,2/22,0.00251803209945536,0.0150562744091145,0,0,30.169696969697,180.543841637112,SERPINE1;ICAM1,1/22,0.003296484417552,0.0101910958013494,0,0,475.619047619048,2718.11467997229,PLAU
Proteins Involved in Diabetic Nephropathy,7/175,2.15363988639551e-06,0.000210609628872963,0,0,13.5,176.152740887707,ZEB2;TGFB1;SERPINE1;ELMO1;ILK;DKK1;ICAM1,1/175,0.0260220999459419,0.0279319788410569,0,0,56.9626436781609,207.845812845536,CCL2
Coagulation,6/138,7.45303612683167e-06,9.68894696488118e-05,0,0,14.5161290322581,171.390325279199,SPARC;SERPINE1;PECAM1;ADAM9;FURIN;CLU,1/138,0.0205583666198837,0.0297022864925554,0,0,72.4817518248175,281.554443438429,PLAU
Proteins with Altered Expression in Cancer Metastases,5/106,3.04035224521162e-05,0.00110212768888921,0,0,15.5830583058306,162.0786427943,PDGFRA;SPARC;TGFB1;CDH1;SERPINE1,1/106,0.0158165326939135,0.0188830033182437,0,0,94.7238095238095,392.791174820312,PLAU
Peripheral Tissue Microangiopathy,3/46,0.000513924827247618,0.00634205105965145,0,0,21.3477638640429,161.675871144317,TGFB1;SERPINE1;ICAM1,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,PLAU
Microangiopathy in Diabetic Neuropathy,2/24,0.00299540116935464,0.0165460255069113,0,0,27.4242424242424,159.353417714256,TGFB1;ICAM1,1/24,0.00359580673873441,0.0101910958013494,0,0,434.217391304348,2443.76979314669,CCL2
Proplatelet Maturation,4/79,0.00015154759987734,0.00338067722803296,0,0,16.5475,145.528822076531,TGFB1;SERPINE1;MYL9;ICAM1,1/79,0.0118037291244742,0.0156935944041304,0,0,127.685897435897,566.841082547516,CCL2
Malaria,3/50,0.000657155534456632,0.0153005404064371,0,0,19.5270049099836,143.08588265054,TGFB1;PECAM1;ICAM1,1/51,0.00763080222089554,0.0177648263113934,0,0,199.47,972.528411753474,CCL2
Malaria,3/50,0.000657155534456632,0.0153005404064371,0,0,19.5270049099836,143.08588265054,TGFB1;PECAM1;ICAM1,1/50,0.00748155237341628,0.0361980438307643,0,0,203.551020408163,996.446357764973,CCL2
Interleukin-9 regulation of target genes,2/26,0.00351177582639185,0.0276013257933956,0,0,25.1363636363636,142.061513186742,SOCS2;LCN2,1/26,0.00389506923436901,0.0153069028079862,0,0,399.44,2216.11062530876,CCL2
Malaria,3/51,0.000696535896957325,0.0100660671560284,0,0,19.1192307692308,138.985168421018,TGFB1;PECAM1;ICAM1,1/51,0.00763080222089554,0.0177648263113934,0,0,199.47,972.528411753474,CCL2
Malaria,3/51,0.000696535896957325,0.0100660671560284,0,0,19.1192307692308,138.985168421018,TGFB1;PECAM1;ICAM1,1/50,0.00748155237341628,0.0361980438307643,0,0,203.551020408163,996.446357764973,CCL2
Oncostatin M,9/311,1.04353010710616e-06,9.35002975967118e-05,0,0,9.91525423728813,136.561817566098,LYN;CDKN1A;SERPINB1;CDH3;SERPINE1;TPM1;LCN2;STX11;ICAM1,2/311,0.000715644256726046,0.0098630004527614,0,0,127.430420711974,922.892822752706,PLAU;CCL2
TWEAK regulation of gene expression,2/27,0.00378442261491546,0.0292314022669332,0,0,24.129696969697,134.567988879069,SERPINE1;ICAM1,1/27,0.00404467804622706,0.0153069028079862,0,0,384.057692307692,2116.29358166937,CCL2
Hepatic Stellate Cells in non-Alcoholic Fatty Liver Disease,3/55,0.00086901337221399,0.00787543368568928,0,0,17.6449704142012,124.36443430474,PDGFRA;TGFB1;CDH1,2/55,2.22355362508991e-05,0.000433592956892532,0,0,752.603773584906,8063.26047108095,PLAU;CCL2
Beta2 integrin cell surface interactions Homo sapiens 95b6b434-618d-11e5-8ac5-06603eb7f303,2/29,0.00435830273978445,0.0361372769319662,0,0,22.3400673400673,121.433291414908,TGFBI;ICAM1,1/29,0.00434385079686094,0.00901093861824211,0,0,356.589285714286,1939.48700111416,PLAU
Integrin beta-2 pathway,2/29,0.00435830273978445,0.0308853381130779,0,0,22.3400673400673,121.433291414908,TGFBI;ICAM1,1/29,0.00434385079686094,0.0153069028079862,0,0,356.589285714286,1939.48700111416,PLAU
RAGE/AGER and S100 Proteins in Cardiovascular Injury,2/30,0.00465940411292557,0.0219711738658279,0,0,21.5411255411255,115.651453393229,SERPINE1;ICAM1,2/30,6.5187917475775e-06,0.000276095361914298,0,0,1426.35714285714,17031.8760580581,PLAU;CCL2
Complement and Coagulation Cascades WP558,3/58,0.00101467411963301,0.0106782371637569,0,0,16.68,114.978372211125,SERPINE1;TFPI;CLU,1/58,0.00867513250274921,0.0162768805132773,0,0,174.912280701754,830.360139497581,PLAU
Vascular Endothelial Cell Activation by NO,2/31,0.00496985892934845,0.0225196732736102,0,0,20.7972831765935,110.316356513446,SMPD1;SERPINE1,1/31,0.00464296371323848,0.0115580160521043,0,0,332.783333333333,1787.84597380293,PLAU
Proliferative Diabetic Retinopathy,3/60,0.00111985555442621,0.00914811579672115,0,0,16.0931174089069,109.345580549544,TGFB1;SERPINE1;MYL9,1/60,0.00897337803301339,0.0136348731150983,0,0,168.966101694915,796.42055134622,PLAU
Proteins Involved in Melanoma,7/238,1.61779513447141e-05,0.0007040352721794,0,0,9.78688524590164,107.967560306711,PDGFRA;CDKN1A;SPARC;CDH3;CDH1;ILK;IGF2BP3,1/238,0.0352783986095116,0.0365271914806448,0,0,41.6877637130802,139.424077066813,PLAU
ROS in Triggering Vascular Inflammation,2/32,0.00528960202485264,0.0234196120184315,0,0,20.1030303030303,105.38033146319,SMPD1;ICAM1,2/32,7.43243614212135e-06,0.000276095361914298,0,0,1331.13333333333,15720.2279199713,PLAU;CCL2
AGE-RAGE signaling pathway in diabetic complications,4/100,0.000374898293077499,0.0150896562963693,0,0,12.9140625,101.877176689907,SMAD2;TGFB1;SERPINE1;ICAM1,1/100,0.0149257388776811,0.0361980438307643,0,0,100.494949494949,422.54790984855,CCL2
Autocrine Cytokine/Chemokine Loops in Systemic Scleroderma,2/33,0.00561856855441298,0.024636171225348,0,0,19.4535679374389,100.802131872765,PDGFRA;TGFB1,1/33,0.0049420167963793,0.011679382505168,0,0,311.953125,1656.46540769326,CCL2
Inflammatory Response,6/200,6.06357389074282e-05,0.000337827688198528,0,0,9.84602593947456,95.6110763487818,LYN;CDKN1A;SERPINE1;ITGA5;CHST2;ICAM1,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,CCL2
Beta-1 integrin cell surface interactions,3/66,0.00147589814034224,0.0152607443700437,0,0,14.556043956044,94.8834060906592,ITGA5;TGFBI;NID1,1/66,0.00986775589382722,0.017810096003493,0,0,153.323076923077,708.119996336647,PLAU
Beta1 integrin cell surface interactions Homo sapiens 2fd0bc63-618d-11e5-8ac5-06603eb7f303,3/66,0.00147589814034224,0.0191866758244491,0,0,14.556043956044,94.8834060906592,ITGA5;TGFBI;NID1,1/66,0.00986775589382722,0.0106268140395062,0,0,153.323076923077,708.119996336647,PLAU
Senescence and Autophagy in Cancer WP615,4/105,0.00045124422096662,0.00831041440280191,0,0,12.2716584158416,94.5347433718513,CDKN1A;SPARC;TGFB1;SERPINE1,1/105,0.0156681043562104,0.019941223726086,0,0,95.6394230769231,397.489703543101,PLAU
EGFR1 pathway,5/152,0.000168280327558863,0.00373486801442739,0,0,10.6818918043408,92.8243510386677,CDKN1A;ITGB5;CA2;COTL1;LCN2,1/152,0.0226281213168788,0.0279080162908172,0,0,65.7152317880795,248.966219469226,PLAU
p53 transcriptional gene network WP4963,3/67,0.00154134461264645,0.0131014292074948,0,0,14.3278846153846,92.7744873696917,CDKN1A;SERPINE1;ICAM1,1/67,0.0100167665600723,0.0162768805132773,0,0,150.992424242424,695.092860072288,CCL2
Skin Fibrosis,3/67,0.00154134461264645,0.0111747484416867,0,0,14.3278846153846,92.7744873696917,SMAD2;PDGFRA;TGFB1,1/67,0.0100167665600723,0.0144686628089933,0,0,150.992424242424,695.092860072288,CCL2
N2 Neutrophils in Tumor-Promoting Inflammation and Tumor Progression,2/35,0.00630391415851973,0.0268843397936871,0,0,18.2727272727273,92.5803175676888,SMAD2;TGFB1,1/35,0.00524101004609641,0.011679382505168,0,0,293.573529411765,1541.62536659043,CCL2
Proteins Involved in Myocarditis,6/207,7.33545359966991e-05,0.00202598242276597,0,0,9.49975926817525,90.4396672243805,SOCS2;TGFB1;SERPINE1;LCN2;CLU;ICAM1,2/207,0.000317635362063387,0.00247755582409442,0,0,193.092682926829,1555.28557770728,PLAU;CCL2
Cytokines Trigger Otitis Media,3/71,0.00182124609051164,0.0120036674147358,0,0,13.4823529411765,85.0498419026256,SMAD2;TGFB1;ICAM1,1/71,0.0106126597969387,0.0148130200357778,0,0,142.335714285714,647.016548147989,CCL2
Melanoma,3/71,0.00182124609051164,0.0173599627350896,0,0,13.4823529411765,85.0498419026256,PDGFRA;CDKN1A;CDH1,1/145,0.0215936087756324,0.0242928098725864,0,0,68.9340277777778,264.386667884871,PLAU
Proteins Involved in Neuroblastoma,6/216,9.27456366097201e-05,0.00244511223789262,0,0,9.08847926267281,84.392436576789,CDKN1A;SPARC;SERPINE1;ILK;TGFBI;CLU,1/216,0.0320527344060855,0.0334836600492144,0,0,46.0046511627907,158.273149722992,CCL2
Eosinophil Survival by Cytokine Signaling,3/72,0.00189583813227508,0.0123549001878601,0,0,13.2862876254181,83.2797030961845,LYN;TGFB1;ICAM1,1/72,0.0107615957524882,0.0148130200357778,0,0,140.323943661972,635.916038987997,CCL2
Melanoma,3/72,0.00189583813227508,0.0218671747331404,0,0,13.2862876254181,83.2797030961845,PDGFRA;CDKN1A;CDH1,1/145,0.0215936087756324,0.0242928098725864,0,0,68.9340277777778,264.386667884871,PLAU
Blood coagulation Homo sapiens P00011,2/38,0.00739950571278761,0.0462469107049225,0,0,16.7474747474747,82.1688400298654,SERPINE1;TFPI,1/38,0.00568938773289464,0.00948231288815774,0,0,269.72972972973,1394.2741447062,PLAU
CCKR signaling map ST Homo sapiens P06959,5/165,0.00024647378183054,0.00308092227288175,0,0,9.80753968253968,81.4835399370747,LYN;CDH1;SERPINE1;TCF4;CLU,1/165,0.024547424021947,0.0279369559473935,0,0,60.4664634146341,224.158150565852,PLAU
Proteins Involved in Dilated Cardiomyopathy,5/167,0.000260606024041595,0.00433178859414836,0,0,9.68547912992357,79.9294240501027,TGFB1;CDH1;TPM1;ILK;NEXN,1/167,0.0248424781883714,0.0274204712079194,0,0,59.7319277108434,220.72143485852,CCL2
RANKL regulation of apoptosis and immune response,3/74,0.00205068185407242,0.0182732147918589,0,0,12.9107258938245,79.9120085984779,ADAM9;ICAM1;SNCA,1/74,0.0110594228380556,0.0181866064448026,0,0,136.465753424658,614.706229245501,CCL2
Proteins Involved in Chronic Obstructive Pulmonary Disease,5/170,0.000282949798257022,0.00433733773664971,0,0,9.50793650793651,77.6821333231339,SERPINB1;FUT8;TGFB1;SERPINE1;CTSC,1/170,0.0252849478802057,0.0276480271213464,0,0,58.6627218934911,215.734858585558,CCL2
amb2 Integrin signaling Homo sapiens 5d4f90b6-6188-11e5-8ac5-06603eb7f303,2/40,0.00817421097250093,0.046490824906099,0,0,15.8644338118022,76.2567017103199,LYN;ICAM1,1/40,0.0059882314019792,0.00901093861824211,0,0,255.871794871795,1309.5413986235,PLAU
Proteins Involved in Glomerulonephritis,4/121,0.000769960500484688,0.00720285629485675,0,0,10.5849358974359,75.8852190981411,LYN;TGFB1;SERPINE1;ICAM1,1/121,0.0180411679776536,0.0211081665338547,0,0,82.8208333333333,332.533846973471,CCL2
Proteins with Altered Expression in Cancer-Associated Sustaining of Proliferative Signaling,5/175,0.000323388464117253,0.00480936690225658,0,0,9.22595704948646,74.1458456800533,LYN;PDGFRA;CDKN1A;PECAM1;TCF4,1/175,0.0260220999459419,0.0279319788410569,0,0,56.9626436781609,207.845812845536,PLAU
Alpha-M beta-2 integrin signaling,2/41,0.00857466901915427,0.0451935496538955,0,0,15.4568764568765,73.5583922391537,LYN;ICAM1,1/41,0.00613763080051258,0.0158764156607123,0,0,249.4625,1270.59146099404,PLAU
Proteins Involved in Glioblastoma,5/178,0.000349668370575504,0.00494652816911689,0,0,9.06459308193412,72.1407939686601,PDGFRA;SPARC;TGFB1;CDH1;ILK,1/178,0.0264642127545926,0.0281482990207939,0,0,55.9887005649718,203.348828445737,PLAU
HIF1A in Vasculogenic Mimicry of Cancer,2/42,0.00898378124785379,0.0347372874917013,0,0,15.069696969697,71.0134515924959,SMAD2;TGFB1,1/42,0.00628701524151983,0.0125855500538445,0,0,243.365853658537,1233.6869399593,PLAU
Beta-3 integrin cell surface interactions,2/43,0.00940148598037318,0.0478621104455362,0,0,14.7014042867701,68.6098001803698,PECAM1;TGFBI,1/43,0.00643638472731579,0.0158764156607123,0,0,237.559523809524,1198.67505967293,PLAU
Proteins Involved in Myocardial Ischemia,6/252,0.000214732030996588,0.00433178859414836,0,0,7.74429583005507,65.4092493765865,SMAD2;TGFB1;SERPINE1;PECAM1;TFPI;ICAM1,1/252,0.0373273584359295,0.0382390719072406,0,0,39.3346613545817,129.333497446993,CCL2
Complement and coagulation cascades,3/85,0.00304257303094431,0.0266492379947179,0,0,11.172607879925,64.7458406208639,SERPINE1;TFPI;CLU,1/70,0.0104637089013926,0.0180073129930942,0,0,144.405797101449,658.467662524263,PLAU
Complement and coagulation cascades,3/85,0.00304257303094431,0.0266492379947179,0,0,11.172607879925,64.7458406208639,SERPINE1;TFPI;CLU,1/85,0.0126964037761181,0.0361980438307643,0,0,118.529761904762,517.552677869987,PLAU
Proteins Involved in Endometriosis,6/256,0.000233743219075639,0.00433178859414836,0,0,7.61883870967742,63.7033001021883,CDH3;TGFB1;CDH1;SERPINE1;LCN2;ICAM1,1/256,0.0379122422328197,0.0382390719072406,0,0,38.7098039215686,126.677105782298,CCL2
Proteins with Altered Expression in Melanoma,2/46,0.010705542973315,0.0395491396466416,0,0,13.6969696969697,62.1430643580292,TGFB1;CDH1,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,PLAU
KRAS Signaling Up,5/200,0.000594960540420309,0.00232034610763921,0,0,8.03296703296703,59.6609704498661,TMEM158;CA2;PECAM1;TFPI;GNG11,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,PLAU
Interleukin-4 regulation of apoptosis,6/267,0.000292934548567774,0.00570585555471142,0,0,7.293659621802,59.3380153748299,CDKN1A;CA2;TFPI;ARHGAP25;CTSC;CHST2,1/267,0.039519451132547,0.0443096876334618,0,0,37.0883458646617,119.83104705578,CCL2
Proteoglycans in cancer,5/205,0.000665240887236395,0.0153005404064371,0,0,7.83015873015873,57.2804405112064,SMAD2;CDKN1A;TGFB1;ITGB5;ITGA5,1/205,0.0304372096910159,0.0388862599260917,0,0,48.5122549019608,169.409131892196,PLAU
Melanoma,4/145,0.00150643060437209,0.0111747484416867,0,0,8.77260638297872,57.0045038690651,CDKN1A;TGFB1;CDH1;TCF4,1/145,0.0215936087756324,0.0242928098725864,0,0,68.9340277777778,264.386667884871,PLAU
Eosinophil Survival in Asthma,2/50,0.0125608922452036,0.0433649851322504,0,0,12.5530303030303,54.9467110196934,LYN;TGFB1,1/50,0.00748155237341628,0.0126861105462276,0,0,203.551020408163,996.446357764973,CCL2
Vitamin B12 metabolism WP1533,2/50,0.0125608922452036,0.0495706640391069,0,0,12.5530303030303,54.9467110196934,SERPINE1;ICAM1,1/50,0.00748155237341628,0.0162768805132773,0,0,203.551020408163,996.446357764973,CCL2
Scavenger Receptor OLR1 in Inflammation Related Endothelial Dysfunction,2/51,0.0130451531567722,0.0447703481119992,0,0,12.2962275819419,53.357495224329,SERPINE1;ICAM1,1/51,0.00763080222089554,0.0127543408549254,0,0,199.47,972.528411753474,CCL2
TSH regulation of gene expression,3/97,0.00441219115901112,0.0308853381130779,0,0,9.74042553191489,52.8260665361787,LYST;STX11;ICAM1,1/97,0.0144801405312483,0.0212259397957839,0,0,103.651041666667,438.959796854159,CCL2
Proteins Involved in Multiple Sclerosis,2/54,0.0145460080602241,0.0493373372802924,0,0,11.5850815850816,49.0099772847498,TGFB1;ICAM1,1/54,0.008078462047278,0.0133123952046694,0,0,188.150943396226,906.615436737158,CCL2
DAPK1 human kinase ARCHS4 coexpression,6/299,0.000534030141045295,0.00485204528149726,0,0,6.48651326654189,48.8762554759285,LYN;HHEX;ZEB2;FURIN;TNS3;ICAM1,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
Chagas disease,3/102,0.00507662260532069,0.0355363582372448,0,0,9.24615384615385,48.848439339407,SMAD2;TGFB1;SERPINE1,1/104,0.0155196611008772,0.0220856715666329,0,0,96.5728155339806,402.288317326718,CCL2
Chagas disease,3/102,0.00507662260532069,0.0355363582372448,0,0,9.24615384615385,48.848439339407,SMAD2;TGFB1;SERPINE1,1/102,0.0152227298331673,0.0361980438307643,0,0,98.4950495049505,412.198392406259,CCL2
ROCK1 knockdown 156 GSE34769,6/300,0.000543487820899723,0.0391311231047801,0,0,6.4641211323239,48.5940516872336,ITGB5;FHL1;ALDH1A1;LCN2;LRRC32;ICAM1,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ROCK2 knockdown 157 GSE34769,6/300,0.000543487820899723,0.0391311231047801,0,0,6.4641211323239,48.5940516872336,PHTF2;ITGB5;FHL1;ALDH1A1;LRRC32;GNG11,2/300,0.000666082804060468,0.0106573248649675,0,0,132.208053691275,966.982471333147,PLAU;CCL2
Chagas disease,3/104,0.00535835270407723,0.0342934573060943,0,0,9.06214775323686,47.3868648767473,SMAD2;TGFB1;SERPINE1,1/104,0.0155196611008772,0.0220856715666329,0,0,96.5728155339806,402.288317326718,CCL2
Chagas disease,3/104,0.00535835270407723,0.0342934573060943,0,0,9.06214775323686,47.3868648767473,SMAD2;TGFB1;SERPINE1,1/102,0.0152227298331673,0.0361980438307643,0,0,98.4950495049505,412.198392406259,CCL2
Proteins Involved in Obesity,3/106,0.005649328918916,0.024636171225348,0,0,8.88528752800597,45.9921898250362,CDKN1A;TGFB1;SERPINE1,1/106,0.0158165326939135,0.0188830033182437,0,0,94.7238095238095,392.791174820312,CCL2
Proteins Involved in Diabetes Mellitus Type 2,3/115,0.00707524774521804,0.0293117406587605,0,0,8.16758241758242,40.4389487118322,TGFB1;SERPINE1;ICAM1,1/115,0.0171517164979722,0.0202702104066944,0,0,87.2061403508772,354.55025696917,CCL2
Vitamin D Receptor Pathway WP2877,4/182,0.00343356039918066,0.025523080782599,0,0,6.93609550561798,39.3564986038564,CDKN1A;SERPINB1;TGFB1;TPM1,1/182,0.0270534883841025,0.0285608086348859,0,0,54.7403314917127,197.609275118901,CYP27B1
Interleukin-1 regulation of extracellular matrix,3/120,0.0079515021759071,0.0444398751490803,0,0,7.81656804733728,37.788372914242,SRGN;ALDH1A1;ICAM1,1/120,0.0178929633377612,0.0245199867961913,0,0,83.5210084033613,336.034061491762,CCL2
Receptors and Adaptor Proteins Activated in Cancer,3/125,0.00888910104507376,0.0347372874917013,0,0,7.49432534678436,35.3951691714408,LYN;PDGFRA;PECAM1,1/125,0.0186338374756652,0.0215857325213152,0,0,80.133064516129,319.152056732132,PLAU
Allograft Rejection,4/200,0.00479860511898462,0.0133675428314572,0,0,6.29336734693878,33.6029944353692,SRGN;LYN;TGFB1;ICAM1,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,CCL2
Proteins Involved in Atherosclerosis,4/200,0.00479860511898462,0.0222908138558349,0,0,6.29336734693878,33.6029944353692,TGFB1;SERPINE1;PECAM1;ICAM1,2/200,0.000296535132839628,0.00247755582409442,0,0,199.989898989899,1624.58691694667,PLAU;CCL2
TNF-alpha Signaling via NF-kB,4/200,0.00479860511898462,0.0133675428314572,0,0,6.29336734693878,33.6029944353692,CDKN1A;SERPINE1;SLC2A3;ICAM1,2/200,0.000296535132839628,0.0020757459298774,0,0,199.989898989899,1624.58691694667,PLAU;CCL2
Proteins Involved in Alzheimer's Disease,3/130,0.00988894050959867,0.0372440616595275,0,0,7.19745608721987,33.2258919570884,TGFB1;CLU;SNCA,1/130,0.0193743389965825,0.02222350649608,0,0,77.0077519379845,303.703620326663,CCL2
Ectoderm Differentiation WP2858,3/138,0.0116201038947666,0.0493854415527579,0,0,6.76820512820513,30.1524796438622,SOCS2;ABCC4;SNCA,1/138,0.0205583666198837,0.0233365242712193,0,0,72.4817518248175,281.554443438429,CCL2
CSF1R human kinase ARCHS4 coexpression,5/299,0.00349160335736487,0.0191436184076212,0,0,5.30126336248785,29.9913367774618,LYN;TGFB1;TNS3;STX11;ICAM1,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
PLK3 human kinase ARCHS4 coexpression,5/299,0.00349160335736487,0.0191436184076212,0,0,5.30126336248785,29.9913367774618,LYN;CDKN1A;TGFB1;STX11;ICAM1,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
MicroRNAs in cancer,5/310,0.00406997535418615,0.0309623269868304,0,0,5.1072079104866,28.1106767009118,PDGFRA;CDKN1A;ZEB2;TPM1;ITGA5,1/310,0.0457850030466385,0.047616403168504,0,0,31.8576051779935,98.2424409831854,PLAU
